Highbridge Capital Management’s AMAG Pharmaceuticals AMAG Stock Holding History

Highbridge Capital Management’s Portfolio AMAG Stock Details AMAG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-30,300	Closed	-$560K	–	2109
2017 Q3	$560K	Sell	30,300 -5,000	-14%	-$93.2K	0.01%	860
2017 Q2	$651K	Buy	+35,300	New	+$699K	0.01%	680
2016 Q4	–	Sell	-19,500	Closed	-$477K	–	1720
2016 Q3	$477K	Sell	19,500 -2,700	-12%	-$67.5K	0.01%	806
2016 Q2	$531K	Buy	22,200 +13,300	+149%	+$305K	0.01%	833
2016 Q1	$208K	Sell	8,900 -18,100	-67%	-$430K	﹤0.01%	1330
2015 Q4	$815K	Buy	+27,000	New	+$872K	0.01%	825

Other funds holding AMAG

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Highbridge Capital Management's AMAG Position: Q1 2018 in Review

Highbridge Capital Management sold out of AMAG Pharmaceuticals (AMAG) in Q1 2018, closing a stake of 11,842 shares — an estimated $157K sold.

Highbridge Capital Management first reported a position in AMAG in Q4 2014 and held it in 10 quarters. The position peaked at $22.2M in Q2 2015. 170 funds tracked by Wall St. Rank hold AMAG as of Q1 2018.

Highbridge Capital Management reported no remaining AMAG Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
Highbridge Capital Management sold 11,842 AMAG Pharmaceuticals shares in Q1 2018, an estimated $157K.
Highbridge Capital Management first reported a position in AMAG Pharmaceuticals in Q4 2014 and held it in 10 quarters.
Highbridge Capital Management's AMAG Pharmaceuticals position peaked at $22.2M in Q2 2015.
170 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q1 2018.

Based on Highbridge Capital Management's 13F filing for Q1 2018, filed 15 May 2018.